Navigation Links
Cardiome And Astellas Announce Positive Results From ACT 2 Trial

icensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent eve
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cardiome And Astellas Announce Positive Results From ACT Trial
(Date:7/24/2014)... Many new dentists who are opening their own ... their practice will be a success. DentalDisposables.net is here to ... the most can make all the difference. Dentistry is a ... that purchasing discount dental supplies can make the ... successful dentists across the United States ...
(Date:7/24/2014)... , July 24, 2014  Kinex Pharmaceuticals announced the ... the Company,s KX2-391 Ointment for the commencement of a ... the Company,s third IND to be allowed by the ... KX2-391 is a synthetic, orally active and highly selective ... KX2-391 promotes the induction of p53, G2/M arrest of ...
(Date:7/24/2014)... 2014 Research and Markets  has announced ... by Product, Component, Application and Geography - Global Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 ... witness a moderate growth as the markets of the ... reached the saturation levels. The demand is expected to ...
Breaking Medicine Technology:Dental Supplies Online is Key to Dental Success...Really! 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2
(Date:7/24/2014)... to light at night, which shuts off nighttime production ... to tamoxifen, a widely used breast cancer drug, says ... cancer researchers. The study, "Circadian and Melatonin Disruption by ... Tamoxifen Therapy in Breast Cancer," published in the journal ... that melatonin is vital to the success of tamoxifen ...
(Date:7/24/2014)... 2014 The report, “Content Delivery ... market into various sub-segments with an in-depth analysis ... drivers and restraints for this market with insights ... market data tables and 36 figures spread through ... Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, ... may be dead wrong, according to a small study that asked ... with 33 boys between the ages of 14 and 16, researchers ... for the closeness and trust. Very few boasted about sexual conquests ... with a girl. "In our culture, we have lots of ...
(Date:7/24/2014)... 24, 2014 Pools and beaches are the ... can be dangerous, especially for small children, so Amica ... , According to the Centers for Disease Control and Prevention, ... at risk for water-related injuries and deaths. It’s important to ... water, so Amica is offering the following tips from the ...
(Date:7/24/2014)... Drinking caffeine may worsen the hot flashes and night ... go through menopause, new survey data suggests. "While ... caffeine intake may be useful for those postmenopausal women ... researcher Dr. Stephanie Faubion, director of the Women,s Health ... But caffeine -- a stimulant found in coffee and ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Is Coffee Aggravating Your Hot Flashes? 2
... 24 UCI Medical Affiliates, Inc. (Other OTC: UCIA) announced ... Finance, Chief Financial Officer, and Secretary of UCI Medical Affiliates, ... federal court to criminal charges for falsifying eight of the ... On the eight reports that were submitted to the ...
... and phosphate content is common, but labeling is not ... -- Additives used to "enhance" uncooked meat and poultry ... disease, researchers say. , Many fresh meat and poultry ... and flavorings that are not required to be listed ...
... , , , ... ), a global leader in the field of radiosurgery, announced today ... Ill., has installed the CyberKnife((R)) Robotic Radiosurgery System in one of ... of this new CyberKnife configuration option, which can save hospitals both ...
... 24 Healthcare Informatics Associates (HIA), an InfoLogix company (Nasdaq: ... Hilo Medical Center (HMC) in Hilo, Hawaii for a multi-year engagement ... Region facilities. , , (Logo: ... , Hilo initially selected HIA among multiple competing vendors ...
... Sick people are being used as a "wedge" in a turf ... experts. , , Some hospitals ... hallways on unit floors, believing that will force nurses to find ... CEO and Vice President, respectively, at TeleTracking Technologies, leading maker of ...
... , , , ... hosted by the Kaiser Permanente Health Care Institute and the National ... for all Americans. Speakers discussed proven strategies for incentivizing coordinated care ... the way we cover health care, without actually reforming care delivery ...
Cached Medicine News:Health News:UCI Medical Affiliates, Inc.'s Internal Investigation Leads to Former Executive Officer Pleading Guilty to Criminal Charges 2Health News:Fresh-Meat Additives May Be Dangerous for Kidney Patients 2Health News:First Customer Installs CyberKnife System in Existing Radiation Therapy Vault 2Health News:First Customer Installs CyberKnife System in Existing Radiation Therapy Vault 3Health News:First Customer Installs CyberKnife System in Existing Radiation Therapy Vault 4Health News:Healthcare Informatics Associates, an InfoLogix Company, Selected by Hilo Medical Center for MEDITECH 6.0 EMR Implementation 2Health News:Healthcare Informatics Associates, an InfoLogix Company, Selected by Hilo Medical Center for MEDITECH 6.0 EMR Implementation 3Health News:Are Patients Becoming Victims in Hospital Overcrowding Turf Wars? Experts Ask 2Health News:Teamwork, Technology, and Coordinated Care Improve Outcomes and Lower Costs 2Health News:Teamwork, Technology, and Coordinated Care Improve Outcomes and Lower Costs 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: